NCT02799472 - Mechanistic Study of GSK3196165 Plus Methotrexate (MTX) in Subjects With Active Rheumatoid Arthritis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 15, 2016

Primary Completion Date

October 30, 2017

Study Completion Date

October 30, 2017

Conditions

Arthritis, Rheumatoid

Interventions

DRUG

GSK3196165

GSK3196165 is supplied as liquid and will be administered as SC injection.

DRUG

Placebo

0.9% weight by volume (w/v) sodium chloride solution administered as SC injection.

DRUG

MTX

Capsule, tablet or liquid administered orally or as SC injection.

DRUG

Folic (or folinic) acid

Capsule, tablet or liquid and will be administered orally.

Trial Locations (16)

16635

GSK Investigational Site, Duncansville

33015

GSK Investigational Site, Miami

33309

GSK Investigational Site, Fort Lauderdale

33781

GSK Investigational Site, Pinellas Park

38119

GSK Investigational Site, Memphis

60616

GSK Investigational Site, Chicago

66346

GSK Investigational Site, Püttlingen

77024

GSK Investigational Site, Houston

79106

GSK Investigational Site, Freiburg im Breisgau

92020

GSK Investigational Site, El Cajon

82-300

GSK Investigational Site, Elblag

67-100

GSK Investigational Site, Nowa Sól

05-500

GSK Investigational Site, Piaseczno

00-660

GSK Investigational Site, Warsaw

03-291

GSK Investigational Site, Warsaw

51-128

GSK Investigational Site, Wroclaw